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Abstract
The drug discovery stage is a vital part of the drug development process and
forms part of the initial stages of the development pipeline. In recent times,
machine learning-based methods are actively being used to model drug-target
interactions for rational drug discovery due to the successful application of these
methods in other domains. In machine learning approaches, the numerical rep-
resentation of molecules is vital to the performance of the model. While sig-
nificant progress has been made in molecular representation engineering, this
has resulted in several descriptors for both targets and compounds. Also, the
interpretability of model predictions is a vital feature that could have several
pharmacological applications. In this study, we propose a self-attention-based,
multi-view representation learning approach for modeling drug-target interac-
tions. We evaluated our approach using three large-scale kinase datasets and
compared six variants of our method to 16 baselines. Our experimental re-
sults demonstrate the ability of our method to achieve high accuracy and offer
biologically plausible interpretations using neural attention.
Keywords: Drug-Target Interactions, Machine Learning, Representation
Learning, Self-Attention, Drug Discovery
IThis work was supported by SipingSoft Co. Ltd., Chengdu, PRC
∗Corresponding author
Email address: brighteragyemang@gmail.com (Brighter Agyemang)
Preprint submitted to Journal of Biomedical Informatics May 4, 2020
ar
X
iv
:2
00
5.
00
39
7v
1 
 [c
s.L
G]
  1
 M
ay
 20
20
1. Introduction
In the pharmaceutical sciences, drug discovery is the process of elucidating
the roles of compounds in bioactivity for developing novel drugs. The drug
discovery stage is a vital part of the drug development process and forms part
of the initial stages of the development pipeline. In recent times, traditional in
vivo and in vitro methods for analyzing bioactivities have been enhanced with
automated methods such as large-scale High-Throughput Screening (HTS). The
automation is motivated by the quest to reduce the cost and time-to-market
challenges that are associated with the drug development process. The cost of
developing a single drug is estimated to be 1.8 billion US dollars and could take
10-15 years to complete [1]. While HTS provides a better alternative to wet-
lab experiments, it is time-consuming (takes about 2-3 years) [2] and requires
advanced chemogenomic libraries. Also, with HTS, an exhaustive screening of
the known human proteome and the 1060 synthetically feasible compounds is
intractable [3, 4]. Additionally, HTS has a high failure rate [5].
Lately, the availability of large-scale chemogenomic and pharmacological
data (such as DrugBank [6], KEGG [7], STITCH [8], and ChemBL [9], Davis [10],
KIBA [11], PubChem [12]), coupled with advances in computational resources
and algorithms have engendered the growth of the in silico (computer-based)
Virtual Screening (VS) domain. In silico methods have the potential to address
the challenges mentioned above that plague HTS due to their ability to analyze
assay data, unmask inherent relationships, and exploit such latent information
for drug discovery tasks [13].
In VS, data-driven models are used to examine and predict Drug-Target In-
teractions (DTI) to systematically guide subsequent HTS or in vitro validation
methods. DTI research using VS methods has applications in drug side-effects
studies [14] and could be a key contributor in developing personalized medi-
cations [15], and in drug-repurposing [16]. Also, it is worth noting that the
use of in silico methods to optimize the drug development process could reduce
healthcare costs and encourage accessibility of healthcare services.
2
Consequently, there are several in silico proposals in the literature about DTI
prediction [3]. On account of data usage, structure-based methods, ligand-based
approaches, and proteochemometric Modeling (PCM) constitute the taxonomy
of existing in silico DTI studies. Structure-based methods use the 3D conforma-
tions of targets and compounds for bioactivity studies. Docking simulations are
well-known instances of structure-based methods. Since the 3D conformations
of several targets, such as G-Protein Coupled Receptors (GPCR) and Ion Chan-
nels (IC), are unknown, structure-based methods are limited in their application.
They are also computationally expensive since a protein could assume multi-
ple conformations depending on its rotatable bonds [3]. Ligand-based methods
operate on the assumption that similar compounds would interact with simi-
lar targets and vice-versa, tersely referred to as ‘guilt-by-association.’ Hence,
ligand-based methods perform poorly when a target has a few known binding
ligands (< 100). The same applies in reverse.
On the other hand, PCM or chemogenomic methods, proposed in [17], model
interactions using a drug (compound)-target (protein) pair as input. Since PCM
methods do not suffer from the drawbacks of ligand-based and structure-based
methods, there have been many studies in using such chemogenomic methods
to study DTIs [18, 19, 20]. Also, PCM methods can use a wide range of drug
and target representations. Qiu et al. provide a well-documented growth of the
PCM domain [21].
As regards computational methodologies, Chen et al. categorize existing
models for DTI prediction into Network-based, Machine Learning (ML)-based,
and other models [22]. Network-based methods approach the DTI prediction
task using graph-theoretic algorithms where the nodes represent drugs and
targets while the edges model the interactions between the nodes [23]. As a
corollary, the DTI prediction task becomes a link prediction problem. While
network-based methods can work well even on datasets with few samples, they
do not generalize to samples out of the training set, among other shortcomings.
ML methods tackle the DTI prediction problem by training a parametric or
non-parametric model iteratively with a finite independent and identically dis-
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tributed training set made up of drug-target pairs using supervised, unsuper-
vised, or semi-supervised algorithms. Probabilistic Matrix Factorization (MF)
of an interaction matrix and certain forms of similarity-based methods also exist
in the domain [24, 25].
Rifaioglu et al., in their analysis of recent progress of in silico methods, show
that researchers in the domain [3] are increasingly studying supervised ML meth-
ods. In this context, similarity-based and feature-based methods have been the
main ML approaches. Similarity-based methods leverage the drug-drug, target-
target, and drug-target similarities to predict new interactions [26, 27, 28].
Feature-based methods represent each drug or target using a numerical vec-
tor, which may reflect the entity’s physicochemical and molecular properties.
These feature vectors are used to train an ML model to predict unknown in-
teractions. Sachdev et al. provide a thorough discussion of the feature-based
DTI methods [29]. Additionally, some proposals combine feature-based and
similarity-based methods to model interactions [30, 31]. Due to the recent suc-
cess of the Deep Learning (DL) domain, a form of ML, in areas such as computer
vision [32] and Natural Language Processing (NLP) [33], recent feature-based
approaches have mainly been DL algorithms [34, 35, 36, 37, 2, 15].
In feature-based methods, the construction of numerical vectors from the
digital forms of drugs or targets is significant. This process is called featur-
ization. The 2D structure of a compound can be represented using a line no-
tation algorithm, such as the Simplified Molecular Input Line Entry System
(SMILES) [38]. Likewise, a target can be encoded using amino-acid sequencing.
The compound and target features can then be computed using libraries such as
RDKit [39] and ProPy [40], respectively. While Wen et al. draw a line between
descriptors and fingerprints, we refer to both as descriptors herein since they
can be composed to form molecular representations [14].
While significant progress has been made in molecular representation en-
gineering, this has resulted in several descriptors for both targets and com-
pounds [41, 3, 42]. Since the choice of descriptors or features significantly af-
fects model skill, there is an inexorable dilemma for researchers in feature selec-
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tion [43, 44]. In some instances, the performance of molecular descriptors tends
to be task related [45] and offer complementary behaviors [46, 47, 42]. There-
fore, the integration of these predefined descriptors is common and espoused by
researchers to construct joint molecular views [48, 3]. Although these descrip-
tors tend to provide domain-related information, their predefined nature means
they are unable to establish a closer relationship between the input and output
space concerning the task at hand.
Indeed, several algorithms have been proposed to learn compound and tar-
get features directly from their sequences, 2D or 3D forms over the past few
years [49, 34, 35, 36, 50, 51, 2, 15] using backpropagation. It has been shown
that DTI models constructed in such manner usually outperform predefined
descriptors or provide competitive results [35, 52, 53]. Nonetheless, the pro-
liferation of these end-to-end descriptor learning methods only exacerbates the
dilemma mentioned above since these studies also demonstrate the capabilities of
predefined methods such as the Extended Connectivity Fingerprint (ECFP) [54]
method.
In another vein, most of the existing DTI studies in the literature have formu-
lated the DTI prediction task as a Binary Classification (BC) problem. However,
the nature of bioactivity is continuous. Also, DTI depends on the concentration
of the two query molecules and their intermolecular associations [55]. Indeed,
it rare to have a ligand that binds to only one target [3]. While the binary clas-
sification approach provides a uniform approach to benchmark DTI proposals
in the domain using the GPCR, IC, Enzymes (E), and Nuclear Receptor (NR)
datasets of [23], treating DTI prediction as a binding affinity prediction problem
leads to the construction of more realistic datasets [56, 11]. Accordingly, the
Metz [57], KIBA [11], and Davis [10] datasets serve as the benchmark datasets
for regression-based DTI proposals and their output values are measured in
dissociation constant (Kd), KIBA metric [11], and inhibition constant (Ki), re-
spectively. Another significant feature of the regression-based datasets is that
they do not introduce class-imbalance problems seen with the BC datasets men-
tioned above. The BC-based algorithms typically address the class-imbalance
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problem using sampling techniques [42] or assume samples without reported
interaction information to be non-interacting pairs. We argue that predicting
continuous values enable the entire spectrum of interaction to be well-captured
in developing DTI prediction models.
Furthermore, since in silico DTI models are typically not replacements for
in vitro and in vivo validations, interpretability of their prediction is vital to
guiding domain experts to realizing the benefits above of advances in the do-
main. However, the application of multiple levels of non-linear transformation
of the input means that DL models do not lend themselves easily to interpreta-
tion. In some studies, less powerful alternatives such as decision trees and L1
regularization of linear models have been used to achieve the interpretability
of prediction results [58, 59]. Recent progress in pooling and attention-based
techniques [33, 60, 61] have also aided the ability to gain insights into DL-based
prediction results [62, 15]. We posit that such attention-based mechanisms offer
a route to provide biologically plausible insights into DL-based DTI prediction
models while leveraging the strength of DL-models. Also, since attention-based
methods can learn rich molecular representations, it could facilitate accurate
predictions in other domains such as ligand-catalyst-target reactions [3].
To this end, our contributions to the domain are as follows:
• We propose a multi-view attention-based architecture for learning the rep-
resentation of compounds and targets from different unimodal descriptor
schemes (including end-to-end schemes) for DTI prediction.
• Our usage of neural attention enables our proposed approach to lend itself
to the interpretation and discovery of biologically plausible insights in
compound-target interactions across multiple views.
• We also experiment with several baselines and show how these seemingly
different compound and target featurization proposals in the literature
could be aggregated to leverage their complementary relationships for
modeling DTIs.
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The rest of our study is organized as follows: section 2 discusses the related
work and baseline models of our study, we discuss the various featurization
methods we use and our proposed architecture in section 3. The experiments
we conducted are described in section 4 and we discuss the results in section 5.
Finally, we conclude our work in section 6.
2. Related Work
In silico methods provide a promising route to tackle some critical challenges
in drug discovery effectively. Over the last decade, several studies have been
conducted in modeling interactions, which has led to substantial progress in
DTI prediction and other related tasks. We review some of these notable works
which relate to our study in what follows.
One of the seminal works on integrating unimodal representations of drugs
and compounds is [63]. The authors note that the challenges with DTI predic-
tion mean that the development of models that can leverage heterogeneous data
is vital to the domain. Hence, the chemical space, genomic space, and phar-
macological space are integrated. Subsequently, the compound-target pairwise
relationships are studied using network or graph analysis. Shi et al [26] also
augment similarity information with non-structural features to perform DTI
prediction using a network-based approach.
Additionally, Luo et al. [64] argue that multi-view representations enable
modeling of bioactivities using diverse information. As a result, a DTI model
is proposed in [64] that learn the contextual and topological properties of drug,
disease, and target networks. Likewise, Wang et al. [65] also propose a random
forest-based DTI prediction model that integrates features from drug, disease,
target, and side-effect networks learned using GraRep [66]. These network-
based DTI models are not scalable to large datasets and unable used on samples
outside the dataset.
Also, other researchers have adopted collaborative filtering methods to pre-
dict DTIs. In [67], the authors propose a Matrix Factorization (MF) method for
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predicting the probability that a compound would interact with a given target.
Noting that traditional MF methods are unable to detect nonlinear properties,
a deep MF (DMF) method is proposed in [68]. The DMF approach first con-
structs negative samples using a K-Nearest Neighbor (kNN) method and then
builds an interaction matrix. The rows and columns of the interaction matrix
then serve as the features of drugs and targets in a DL model, which finds the
low-rank decomposition of the interaction matrix.
Similarly, Yasuo et al. [69] use a probabilistic MF approach to decompose
an interaction matrix into a target-feature matrix and a feature-ligand matrix.
While these DL-based MF are able to learn nonlinear properties, viewing DTI
prediction as a BC problem, as seen in these works, does not address the entire
spectrum of bioactivity. In [70], the graph-regularized MF approach of [16]
is also extended to a multi-view approach that integrates both chemical and
structural views of compounds and targets. As mentioned earlier, in the BC
setting, true-negatives are mostly lacking and using kNN, as in [68], introduces
arbitrariness in determining negative samples.
On the other hand, similarity-based ML methods have also been proposed
for DTI prediction. In this setting, compound and target similarity matrices
are constructed and used in kernel-based algorithms such as Support Vector
Machines (SVM) [71, 72], and other well-known ML algorithms such as kNN
and Regularized Least Squares (RLS). While compound similarities are typically
constructed by considering their topological and chemical properties [73], target
similarities are usually computed using metrics such as the Smith-Watermann
(SW) score, which considers the alignment between sequences [74]. Nonetheless,
these approaches use the BC problem formulation. Conversely, the work in [55]
proposed a Kronecker RLS (KronRLS) method that predicts binding affinity
measured in Kd and Ki.
Concerning ensemble ML algorithms, SimBoost is proposed in [31] as a
GBT-based DTI prediction model. While KronRLS is a linear model, Sim-
Boost can learn non-linear properties for predicting real-valued binding affini-
ties. While [31] uses a feature-engineering step to select compound-target fea-
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tures for GBT training, the work in [42] integrates different representations of
a target and uses a feature-selection algorithm to construct representations for
GBT training. The work in [75] also proposes a feature-selection method for
determining feature-subspaces for GBT training. Additionally, [76] proposes
an AdaBoost model for DTI prediction. However, as noted in [77], Boosting
methods are not well-suited for predicting probabilities.
In another vein, several DL methods have been proposed to learn the features
of compounds and targets for DTI prediction [50, 34, 36, 35], whereas others have
proposed DL models that take predefined features as inputs. The work in [14]
proposed a deep-belief network to model interactions using ECFP and Protein
Sequence Composition (PSC) of compounds and targets, respectively. [78] also
propose a DTI model that uses generative modeling to oversample the minority
class in order to address the class imbalance problem. In [2], the sequence of
a target is processed using a Convolutional Neural Network (CNN), whereas a
compound is represented using its structural fingerprint. The compound and
target feature vectors are concatenated and serve as input to a fully connected
DL model. Using CNN means the temporal structure in the target sequence is
sacrificed to capture local residue information.
In contrast, [62] used a Recurrent Neural Network (RNN) and Molecular
Graph Convolution (MGC) to learn the representations of targets and com-
pounds, respectively. These representations are then processed by a siamese
network to predict interactions. A limitation of the approach in [62] is that ex-
tending it to multi-task networks require training several siamese models. While
all these works formulate the DTI prediction as a BC problem, [56] proposes
a DL model that predicts binding affinities given compound and protein en-
coding. The work in [15] also proposed a self-attention based DL model that
predicts binding affinities. Using self-attention enables atom-atom relationships
in a molecule to be adequately captured. Nonetheless, these studies do not
leverage other unimodal representations of compounds and targets. Also, they
do not adopt the split schemes proposed in [55] for developing chemogenomic
models.
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In what follows, we provide an introduction to the existing regression ML
models for DTI prediction that are used as baselines in this study for complete-
ness.
2.1. KronRLS
The KronRLS method proposed in [55] is a generalization of the RLS method
in which the data is assumed to consist of pairs (compounds and targets, in
this case). It is a kernel-based approach for predicting the binding affinity
between a compound-target pair. Specifically, given a set of compound-target
pairs X = {x1, x2, ..., xm} as training data with their corresponding binding-
affinity values Y = {y1, y2, ..., ym}, where i < m and m ∈ R, KronRLS learns a
real-valued function f(x) that minimizes the objective,
J(f) =
m∑
i=1
(yi − f(xi))2 + λ‖f‖2k (1)
where λ is a regularization parameter and ‖f‖k is the norm of the minimizer
f associated with the kernel k in equation 2. Basing on the representer theo-
rem, [55] defines the minimizer as,
f(x) =
m∑
i=1
aik(x, xi) (2)
where the kernel function k is a symmetric similarity measure between two
compound-target pairs. Given a dataset of m samples, k can be represented as
K ∈ Rm×m computed as Kc ⊗Kt if X contains all possible compound-target
pairs. Here, Kc and Kt are the kernel matrices of the compounds and targets,
respectively. In this context, the parameters ai of f can be determined in closed
form by solving a system of |C||T | linear equations:
(K + λI)a = y (3)
where C is the set of compounds, T is the set of targets, a ∈ Rm, y ∈ Rm, and
I ∈ R|C|×|T | is an identity matrix. Equation 3 assumes that Y contains the
binding affinities of all |C| × |T | pairs in order to be solved in closed form. In
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cases where this assumption does not hold, conjugate gradient with Kronecker
algebraic optimization could be employed to determine a. Howbeit, other im-
putation strategies have been employed to maintain the closed-form evaluation
of equation 3 [55].
2.2. SimBoost
SimBoost, proposed in [31], is a gradient boosting approach to predict the
binding affinity between a compound and a target. The authors propose three
types of features to construct the feature vector of a given compound-target in
training set X = {x1, x2, ..., xm|i < m,m ∈ R}:
1. Type 1: features for each compound and target based on average similarity
values, and information about their frequency in the dataset.
2. Type 2: features for entities determined from their respective similarity
matrices.
3. Type 3: features for each compound-target pair computed using a compound-
target network.
Given compound ci and target ti, the feature vector xi ∈ Rd of the pair ci − ti
is constructed by concatenating the type 1 and type 2 features of both ci and
ti, and the type 3 features of the pair ci− ti. The corresponding binding affinity
yˆi of xi is computed as,
yˆi = φ(xi) =
K∑
k=1
fk(xi), fk ∈ F (4)
where F is the space of all possible trees and K is the number of regression
trees. Using the additive ensemble training approach, the set of trees {fk} are
learned by minimizing the following regularized objective:
L(φ) =
∑
i
l(yˆi, yi) +
∑
k
Ω(fk) (5)
where Ω determines model complexity to control overfitting, l(·) is a differ-
entiable loss function which evaluates the prediction error and yi is the true
binding affinity corresponding to xi.
11
2.3. PADME
In [52], PADME is proposed to model DTIs. The authors propose two vari-
ants of PADME: PADME-ECFP and PADME-GraphConv. The former variant
constructs feature vectors of compounds using the ECFP scheme, whereas the
latter learns the representations of compounds using Molecular Graph Convo-
lution [37]. On the other hand, targets are represented using PSC [40]. After
that, for a given compound-target pair, the feature vector xi ∈ Rd is con-
structed as the concatenation of the compound and target feature vectors. This
constructed feature vector then becomes an input to a Fully Connected Neural
Network (FCNN) which minimizes the regularized Mean Square Error (MSE)
objective,
argmin
θ
N∑
i=0
(yi − f(xi; θ))2 + λ‖f‖2k (6)
where f(xi; θ) outputs yˆi as the predicted value using parameters θ and λ is a
regularization parameter to control overfitting.
2.4. IVPGAN
In our previous study [53], we propose IVPGAN to predict DTIs using a
multi-view approach to represent a compound and PSC to construct the target
feature vector. While ECFP is used to represent predefined compound features,
MGC is used to learn the representation of a compound given the graphical
structure encoded in its SMILES notation. Using an Adversarial Loss (AL)
training technique, the following objective is minimized:
LG = L
MSE
G + λL
AL
G (7)
where
LMSEG =
N∑
i=0
(yi − f([vci , g(di; θg), vpi ]; θf ))2 + β(‖f‖2k + ‖g‖2k) (8)
LALG = Ex∼G [−logD(x)] (9)
, θf and θg are trainable parameters, g(·) ∈ Rd, [· · · ] is a concatenation opera-
tor, ‖ · ‖2k is a norm operator, λ is a hyperparameter that is used to control the
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combination of MSE and the AL objectives, and β is a regularization parameter
that controls overfitting. LMSEG is the MSE objective of the DTI prediction
model, which is treated as the generator of a Generative Adversarial Network
(GAN). LALG is the generator objective component of the GAN whose discrimi-
nator objective is expressed as,
LALD = Ex∼p [−logD(x)] + Ex∼G [−log(1−D(x))] (10)
where the distributions p and G of equations 9 and 10 are derived from the
neighborhood alignment matrices constructed from the labels and predicted
values, respectively, as explained in [53].
3. Methods
3.1. Problem Formulation
We consider the problem of predicting a real-valued binding affinity yi be-
tween a given compound ci and target ti, i ∈ R. The compound ci takes the
form of a SMILES [38] string, whereas the target ti is encoded as an amino acid
sequence. The SMILES string of ci is an encoding of a chemical graph structure
di = {Vi, Ei}, where Vi is the set of atoms constituting ci and Ei is a set of
undirected chemical bonds between these atoms. Therefore, each data point in
the training set is a tuple < ci, ti, yi >. In this study, we refer to the SMILES of
a compound and the amino acid sequence of a target as the ‘raw’ form of these
entities, respectively.
In order to use the compounds and targets in VS models, their respective raw
forms have to be quantized to reflect their inherent physicochemical properties.
Accurately representing such properties is vital to reducing the generalization
error of VS models [3]. We discuss the featurization methods considered in our
study in sections 3.2 and 3.3.
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3.2. Compound Featurization
3.2.1. Extended Connectivity Fingerprint
The ECFP algorithm is a state-of-the-art circular fingerprint scheme for
numerically encoding the topological features of a compound [54]. ECFP de-
composes a compound into substructures and assigns a unique identifier to each
fragment. In the algorithm, larger substructures are composed through bond
relations. A diameter parameter controls the extent to which these larger sub-
structures can be composed. For instance, with a diameter of 4, (written as
ECFP4), the largest substructure has a width of 4 bonds. Subsequently, the
unique identifiers of all fragments are hashed to produce a fixed-length binary
vector. This final representation indicates the presence of particular substruc-
tures. We use RDKit’s [39] implementation of the ECFP algorithm in our study.
3.2.2. Molecular Graph Convolution
Motivated by recent progress in end-to-end representation learning, MGC
is a class of algorithms that, for a given layer, apply the same differentiable
function to the atoms of a molecule to learn the features of the molecule from its
raw form. This operation is akin to the use of kernels in the CNN architecture.
Also, information about distant atoms is propagated radially through bonds,
as found in circular fingerprints. Thus, composing several layers facilitate the
learning of useful representations that are related to the learning objective. The
earliest form of MGC is the work in [49]. It has been used in a notable number
of studies and in various forms, such as that of [62], to model bioactivity. In [37],
graph pool, and gather operations are proposed to augment the neural graph
fingerprints algorithm of [49]. Recent progress in the domain has also produced
other forms of MGCs [50]. In our study, we use the GraphConv algorithm
proposed by [37]. Atom vectors are initialized using predefined physicochemical
properties. The main operations of GraphConv are:
1. Graph convolution: applies molecular graph convolution to each atom.
2. Graph pool: applies a pooling function to an atom and its neighbors to
get the updated feature vector of the atom.
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3. Graph gather: takes the feature vectors of all atoms and applies a down-
sampling function to compute the fixed-length compound feature vector
xmolecule ∈ Rd.
We refer to the GraphConv implementation without the graph gather operation
as GraphConv2D in this study. Hence, for a compound of n ∈ R atoms, where
ai ∈ Rd, i < n, is the vector the ith atom, the output of GraphConv2D is
xmolecule ∈ Rn×d.
3.2.3. Weave
Weave featurization, proposed in [35], is another form of MGC. In the weave
algorithm, atom-atom pairs are constructed using all atoms in a molecule. The
features of an atom are then updated using the information of all other atoms
and their respective pairs. This form of update enables the propagation of infor-
mation from distant atoms, albeit with increased complexity. While predefined
physicochemical features are used to initialize atom vectors, topological prop-
erties are used to initialize atom-atom pair vectors. The following are the main
operations of the weave featurization scheme:
1. Weave: applies the weave operation as described above.
2. Weave gather: computes the compound feature vector xmolecule ∈ Rd as
a function of all atom feature vectors.
We refer to the Weave implementation without the graph gather operation as
Weave2D in this study. Thus, for a compound of n ∈ R atoms, where ai ∈
Rd, i < n, is the vector the ith atom, the output of Weave2D is xmolecule ∈ Rn×d.
3.2.4. Graph Neural Network
In [51], a Graph Neural Network (GNN) is proposed for molecular graphs.
GNN maps a given molecular graph to a fixed-length feature vector using two
differentiable functions: transition and output functions. Atoms are depicted as
nodes, and the bonds within a molecule form the edges in the molecular graph.
For each entity in the graph, substructures within a specified radius are encoded
15
to form the embedding profile of the entity. These profiles are then mapped to
indices of an embedding matrix that is trained using backpropagation. The
transition function is used to update the features of atoms and bonds towards
determining the vector representation of the molecule. Thus, applying different
transition functions hierarchically recapitulates the convolution operation in a
CNN since the same transition function is applied to all entities in the graph
in a layer. The output function downsamples the set of node vectors from the
transition phase to get the fixed-length molecular representation, xmolecule ∈ Rd.
In our study, we use a variant of GNN dubbed GNN2D. This variant omits
the downsampling phase of the GNN operation. Thus, for a compound of n ∈ R
atoms, where ai ∈ Rd, i < n, is the vector the ith atom, the output of GNN2D
is xmolecule ∈ Rn×d.
3.3. Target Featurization
3.3.1. Protein Sequence Composition
As regards target quantization, PSC is a well-known predefined scheme for
capturing subsequence information. It consists of Amino Acid Composition
(AAC), Dipeptide Composition (DC), and Tripeptide Composition (TC). AAC
provides information about the frequency of each amino acid. DC determines
the frequency of every two amino acid combinations, whereas TC computes the
frequency of every three amino acid combinations. The dimension of a PSC
feature vector is 8420.
3.3.2. Prot2Vec
Similar to compound featurization, efforts have been made to learn protein
representations directly from their raw forms. Learning protein vectors is typi-
cally achieved by learning embedding vectors using NLP techniques such as the
word2vec and GloVe models [79, 80]. This approach also maintains the tempo-
ral properties in the target sequence. In [81], it is shown that the NLP approach
could be used to develop rich target representations. Therefore, we construct
a vocabulary of n-gram subsequences (biological words) following the splitting
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scheme of [81]. We set n = 3 in this study. In Figure 1, the approach we use to
construct the 3-gram profile of a protein sequence is illustrated. The raw form
of the protein is split into three non-overlapping representations. The words of
all three sequences make up the vocabulary used in this study. We then move
across the three splits to construct the overlapping 3-gram target profile. Each
word in the dictionary D is mapped to a randomly initialized vector xi ∈ Rd,
i < |D|, that is updated during training.
In order to make computations tractable, we group subsequences using a
non-overlapping window approach similar to the method in [51].
Specifically, given the target profile S = {s1, s2, ..., sn|n ∈ R, n ≤ |D|}, we re-
trieve the vectors of each word to construct the set of vectors X = {x1, x2, ...xn}.
Setting the window size to 3, for didactic purposes, we group X as:
X = {[x1, x2, x3], [x4, x5, x6], ..., [xn−2, xn−1, xn]}
where [· · · ] is a concatenation operator. Also, xi:i+w−1 denotes the window
{xi, ..., xi+w−1} where w is the window size. Note that if |xi:i+w−1| < w by
k elements, we add z ∈ Rd to the window k times. Here, z is a vector of all
zeros. Thus, each window is a wd-dimensional vector. Pooling functions or
RNN could then be used to process these windows/segments into a fixed-length
representation of the target. In section 3.4 we show how we use our proposed
approach to construct the fixed-length vector of a target.
3.3.3. Protein Convolutional Neural Network
Protein Convolutional Neural Network (PCNN), proposed by Tsubaki et
al. [51], is another end-to-end representation learning scheme for target se-
quences. It uses a similar approach to the Prot2Vec method (see section 3.3.2),
but with overlapping windows, to construct target representations. The subse-
quent discussion on the PCNN uses Prot2Vec to encode target data and also has
a minor variation of the convolution operation in [51]. Given c
(l−1)
i = xi:i+w−1
to be the ith window of C(l−1) = {c(l−1)1 , c(l−1)2 , .., c(l−1)|C| }, where l denotes the
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Original Protein
Sequence MRHSKRTYCPDWDDKDWDYGKWRSSSSHKRRKRSHSSAQENKRCKYNHSKMC...
3-gram split 1
3-gram split 2
3-gram split 3 HSK RTY CPD WDD KDW DYG KWR ...
RHS KRT YCP DWD DKD WDY GKW ...
MRH SKR TYC PDW DDK DWD YGK ...
MRH, RHS, HSK, SKR, KRT, RTY, TYC, YCP, CPD, PDW, DWD, WDD, DDK, DKD, KDW, DWD,
WDY, DYG, YGK, GKW, KWR,...
Final 3-gram
protein profile
Figure 1: Target sequence 3-gram representation. The original target sequence is split
into three non-overlapping sequences (split 1, split 2, and split 3). The overlapping 3-gram
profile of the protein is constructed by moving across the three sequences as depicted by the
arrow.
lth convolution layer, PCNN computes c
(l)
i of C
(l) as,
c
(l)
i = f(W
lc
(l−1)
i + b
(l)) (11)
where f(·) is a nonlinear activation function, we let W l ∈ Rwd×wd be the ker-
nel, and b ∈ Rwd. Applying equation 11 multiple times enable nonlinear prop-
erties to be learned at different levels of abstraction. In order to produce a
d-dimensional vector c
(L)
i for the last PCNN layer L, we let W
L ∈ Rd×wd and
bL ∈ Rd. Thus, the final output is CL ∈ R|C|×d. We refer to the rows of CL as
segments.
To compute the vector representation of the target, [51] propose using the
average pooling function. It is easy to realize that other differential pooling
functions, such as the max and sum functions, could be employed. Moreover, an
attention mechanism is proposed in [51], where the compound representation is
used to compute attention weights for the segments of the target representation.
In this context, the compound vector dimension and the segment dimension
must be equal. In this study, we refer to the attention variant as PCNN with
Attention (PCNNA). We refer the reader to [51] for the exposition of PCNNA.
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Additionally, we use a variant of the PCNN architecture called PCNN2D.
This variant omits the downsampling and attention phases of the PCNN method.
3.4. Joint View Attention for DTI prediction
We propose a Joint View self-Attention (JoVA) approach to learn rich rep-
resentations from different unimodal representations of compounds and targets
for modeling bioactivity. Such a technique is significant when one considers that
there exist several molecular representations, and that other novel methods are
likely to be proposed, in the domain.
In Figure 2, we present our proposed DL architecture for predicting binding
affinities between compounds and targets. Before discussing the details of the
architecture, we explain the terminology it uses:
• Entity: this refers to a compound or target.
• View: this refers to a unimodal representation of an entity.
• Segment: for an entity represented as X ∈ R|X|×d, we refer to the rows
as the segments.
• Projector: projects an entity representation X ∈ R|X|×d into X ′ ∈ R|X|×l,
where l ∈ R is the latent space dimension.
• Concatenation function: We denote the concatenation (concat) function
as [· · · ].
• Combined Input Vector (CIV): a vector that is constructed by concate-
nating two or more vectors and used as the input of a function.
For a set of views V = {v1, v2, ..., vJ |J ∈ R}, JoVA represents vj of an entity
as Xvj ∈ R|Xvj |×dj where |Xvj | denotes the number of elements that compose
the entity and dj ∈ R is the dimension of the feature vector of each of these
elements of the j-th view. We write Xvj as Xj in subsequent discussions to
simplify notation. For a compound, the segments are the atoms, whereas a
window of n-gram subsequences is a segment of a target. Note that in the case
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where the result of an entity featurization is a vector before applying the JoVA
method (e.g., ECFP and PSC), this is seen as Xj ∈ R1×dj . Thus, |Xj | = 1.
Thereafter, a projection function pj of vj projects Xj into a latent space of
dimension l to get X ′j ∈ R|X|×l. Note that the dimension of each projection
function is l. We refer to this operation as the latent dimension projection. We
use the format (seg. denotes segment(s)),
(No. of seg., No. of samples, seg. dimension)
to organize N samples at this stage, employing zero-padding where necessary due
to possible variation in the number of segments in a batch. This data structure follows
the usual NLP tensor representation format, where the number of segments is referred
to as sequence length. Hence, the output of vj for a single entity is written as Xj ∈
R|X|×1×l. This enables the concatenation of all projected representations to form the
joint representation [X ′1, X
′
2, ..., X
′
J ] = X¯ ∈ RK×1×l , where K is computed as,
K =
J∑
j=1
|Xj | (12)
X¯ then serves as the input to the joint view attention module. Since we use a single
data point in our discussion, we use X¯ ∈ RK×l in subsequent discussions.
Figure 3 illustrates the detailed processes between the segment-wise concat and
view-wise concat layers of Figure 2. Given the multi-view representation of an entity
X¯, we apply a multihead self-attention mechanism and segment-wise input transforma-
tion [61]. An attention mechanism could be thought of as determining the relationships
between a query and a set of key-value pairs to compute an output. Here, the query,
keys, values, and outputs are vectors. Therefore, given a matrix of queries Q, a matrix
of keys K, and a matrix of values V , the output of the attention function is expressed
as,
Attention(Q,K, V ) = softmax
(
QKT√
dk
)
V (13)
where dk is the dimension of K. In self-attention, we set X¯ as Q, K, and V . The
use of X¯ as query, key, and value enables different unimodal segments to be related
to all other views to compute the final representation of the compound-target pair.
Thus, each view becomes aware of all other views in learning its representation. This
method addresses the challenge of extending the two-way attention mechanism [62] to
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Figure 2: Joint View Attention(JoVA) for Drug-Target Interaction Prediction
multiple unimodal representations. A single computation of equation 13 is referred to
as a ‘head’.
In order to learn a rich representation of a compound-target pair, X¯ is linearly
projected into different subspaces, and the attention representation of each projection
is computed after that. The resulting attention outputs are concatenated and also
linear projected to compute the output of the multihead sub-layer. For a set of self-
attention heads H = {h1, h2, ..., h|H|}, the multihead function is expressed as,
Multihead(Q,K, V ) = concat(H)WO (14)
where hi = Attention
(
QWQi ,KW
K
i , V W
V
i
)
, WQi ∈ Rl×dk , WKi ∈ Rl×dk , WVi Rl×dv ,
dv is the dimension of V , and W
O ∈ R|H|dv×l.
Additionally, a segment-wise transformation sub-layer is used to transform each
segment of the multihead attention sub-layer output non-linearly. Specifically, we
compute
Xˆ = ReLU(aiW1 + b1)W2 + b2 (15)
where ai denotes the i-th segment, W1 ∈ Rl×dseg , W2 ∈ Rdseg×l. We set dseg = 2048
in this study, same as found in [61].
Furthermore, the Add and Norm layers in Figure 3 implements a residual con-
nection around the multihead and segment-wise transformation sublayers. This is
expressed as layerNorm(ai + sublayer(ai)).
At the segments splitter layer, Xˆ is split into the constituting view representations
{Xˆ1, Xˆ2, ..., XˆJ}. Note that Xˆj ∈ R|X|×l for a single sample. To construct the final
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Figure 3: Architecture for constructing of the Combined Input Vector (CIV) using self-
attention and pooling given the set of projected unimodal representations.
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vector representation νj out of Xˆj , pooling functions could then be applied to each
view’s representation. This enables our approach to be independent of the number
of segments of each view, which could vary among samples. In this study, νj ∈ Rl is
computed as,
νj =
m∑
i=1
Xˆ
(i)
j (16)
where m = |Xˆj | and Xˆ(i)j denotes the i-th segment of Xˆj . The view-wise concat layer
subsequently computes the final representation of the compound-target pair as the
concatenation of [ν1, ν2, ..., νJ ] to get x ∈ RJl. We refer to x as the Combined Input
Vector (CIV). The CIV therefore becomes the input to a prediction model. In our
implementation of JoVA, the prediction model is a FCNN with 2-3 hidden layers.
4. Experiments Design
In this section, we present the details of the experiments used to evaluate our
proposed approach for DTI prediction.
4.1. Datasets
The benchmark datasets used in this study are the Metz [57], KIBA [11], and Davis
[10] datasets. These are Kinase datasets that have been applied to benchmark previous
DTI studies using the regression problem formulation [55, 73, 31, 52, 15]. Members
of the Kinase family of proteins play active roles in cancer, cardiovascular, and other
inflammatory diseases. However, their similarity makes it challenging to discriminate
within the family. This similarity results in target promiscuity problems for binding
ligands and, as a result, presents a challenging prediction task for ML models [55]. We
use the version of these datasets curated by [52]. In [52], a filter threshold is applied
to each dataset for which compounds and targets with a total number of samples not
above the threshold are removed. We maintain these thresholds in our study. The
summary of these datasets, after filtering, is presented in table 1. Figure 4 shows the
distribution of the binding affinities for the datasets.
4.2. Baselines
In line with the multi-view representation learning espoused by this study, we use
the following compound and target views listed in Table 3.
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Figure 4: Distribution of the binding affinities (labels) in the Davis, Metz, and KIBA datasets
used in our experiments.
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Figure 5: Structure of each fold in the CV scheme used.
We compare our proposed approach to the works in [55, 31, 52, 51]. While [51] is
a binary classification model, we replace the endpoint with a regression layer in our
experiments. The labels we give to [55, 31] and [51] are KronRLS, SimBoost, and
CPI, respectively. SimBoost and KronRLS are implemented as XGBoost and Numpy
models, respectively, in our experiments.
As discussed in section 2.3, two DL models were proposed for DTI: (1) PADME-
ECFP4 and (2) PADME-GraphConv. Here, we consider these two architectures under
a bigger umbrella of models that use a single view of a compound and a single view
of a target. The nomenclature of such models is compound view-target view.
In summary, the list of baselines used in this study are presented in Table 4.
4.3. JoVA Models
In order to show the versatility of JoVA, we propose six variants using combinations
of the views listed in Table 3. However, other representations not considered herein
could be utilized. The primary condition is ensuring that a view’s representation of an
entity, before the joint view attention module of Figure 2, is in a matrix form. Indeed,
that is the rationale for the 2D variants of the GraphConv, GNN, Weave, and PCNN
models. Nonetheless, as earlier mentioned, the feature vector representations could be
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Table 1: Dataset sizes
Dataset
Number of
compounds
/drugs
Number
of targets
Total number
of pair samples
Filter
threshold
used
Davis 72 442 31824 6
Metz 1423 170 35259 1
KIBA 3807 408 160296 6
Table 2: Simulation hardware specifications
Model # Cores
RAM
(GB)
Avail.
GPUs
# GPUs
used
Intel Xeon
CPU E5-2687W
48 128
1 GeForce
GTX 1080
1
Intel Xeon
CPU E5-2687W
24 128
4 GeForce
GTX 1080Ti
2
Table 3: Compound and target views used in the experiments
View Entity Remark
ECFP8 Compound See section 3.2.1
GraphConv Compound See section 3.2.2
Weave Compound See section 3.2.3
GNN Compoud See section 3.2.4
PSC Target See section 3.3.1
RNN Target
Uses an RNN based on the Prot2Vec
target data organization
PCNN Target See section 3.3.3
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Table 4: Baselines used in experiments
ECFP8-PSC Weave-PCNNA GNN-RNN
Weave-PSC GraphConv-PCNNA CPI (GNN-PCNNA)
GraphConv-PSC ECFP8-RNN SimBoost
GNN-PSC Weave-RNN IVPGAN
ECFP8-PCNNA GraphConv-RNN IntView (Integrated View)
KronRLS
Table 5: JoVA variants used in experiments
Compound Views Target View(s)
ECFP8, GraphConv PSC
ECFP8, GNN PSC
ECFP8, GraphConv PCNN2D
ECFP8, Weave PSC
ECFP8, GNN PCNN2D, PSC
ECFP8, GraphConv RNN, PSC
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treated as a one-row matrix in order to make the JoVA computations possible. The
six variants are shown in Table 5, and they are implemented as Pytorch models herein.
4.4. Model Training and Evaluation
In our experiments, we used a 5-fold Cross-Validation (CV) model training ap-
proach. The structure of each CV-fold is shown in Figure 5. Also, the following three
main splitting schemes were used:
• Warm split: Every drug or target in the validation and test sets is encountered
in the training set.
• Cold-drug split: Every compound in the validation and test sets is absent
from the training set.
• Cold-target split: Every target in the validation and test set is absent from
the training set.
Since cold-start predictions are typically found in DTI use cases, the cold splits provide
realistic and more challenging evaluation schemes for the models.
We used Soek1, a Python module based on scikit-learn, to determine the best
performing hyperparameters for each of all models. We used the warm split of the
Davis dataset and the validation set of each fold for the search. The determined
hyperparameters were then kept fixed for all split schemes and datasets. This was
done due to the enormous time and resource requirements needed to repeat the search
in each case of the experiment. The only exception to this approach is the Simboost
model where we searched. In the case of Simboost, we searched for the best performing
latent dimension of the matrix factorization stage for each dataset. The test set of
each fold was used to evaluate trained models.
As regards evaluation metrics, we measure the Root Mean Squared Error (RMSE)
and Pearson correlation coefficient (R2) on the test set in each CV-fold. Additionally,
we measure the Concordance Index (CI) on the test set, as proposed by [55].
We follow the averaging CV approach, where the reported metrics are the averages
across the different folds. We also repeat the CV evaluation for different random seeds
to minimize randomness. After that, all metrics are averaged across the random seeds.
1https://github.com/bbrighttaer/soek
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5. Results and Discussion
In this section, we discuss the results of all baseline and JoVA models of our study.
Here, performance is to be understood as referring to the CI, RMSE, and R2 results
of a given model. While the smaller RMSE value is desirable when comparing two
models, larger values of CI and R2 connotes the best performance.
In Figure 6, we present the performances of both the baseline and JoVA models
on the Davis dataset. Generally, the cold drug split proved to be the most challenging
scheme on the Davis dataset, with the cold target and warm splits following in that
order. This trend on the Davis dataset implies that the entity with fewer samples may
offer the toughest challenge in the cold splitting schemes of [55].
We realized that the models that utilized multiple unimodal representations of
entities usually resulted in the best or competitive performance on the RMSE, CI, and
R2 metrics. In particular, the IntView and IVPGAN models performed best amongst
all the models, with the IntView model attaining a marginal increase in performance
than the IVPGAN model. While the IVPGAN results observed in this study is an
improvement on the work in [53]. Nonetheless, the ECFP8-PSC model performed
almost as well as the best performing multi-view methods. We argue that the simplicity
(in terms of the number of trainable parameters) of the ECFP8-PSC model makes it
suitable to perform well on the Davis dataset. Thus, we reckon that the susceptibility of
the CPI, ECFP8-PCNNA, GNN-RNN, GraphConv-PCNNA/RNN, and Weave-RNN
models to overfitting accounts for their respective gap in performance, given the size
of the Davis dataset.
Also, while the CPI (GNN-PCNNA) model performed poorly, the GNN-PSC model
attained competitive performance, especially on the warm and cold target splits. Thus,
we show that the GNN method proposed in [51] could be paired with other target rep-
resentations, other than PCNNA, to improve performance. Interestingly, the richness
of the PSC representation is seen in the inability of the PCNNA and RNN baseline
models to perform well on the Davis dataset. An instance of this phenomenon is seen
in the Weave-PSC, and Weave-RNN reported results. While this presents a counter-
intuitive observation, we posit that on more massive datasets, such end-to-end target
representation methods could, at the minimum, produce comparative results to models
that use prefined features.
As regards the traditional ML models, KronRLS recorded modest results for a
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linear model, whereas SimBoost achieved results comparable to that of the multi-view
baseline models. While the performance of GBT is well documented in the literature,
we note that our approach to determining the MF latent dimension also contributes
to the improvement in the results since [31] shows the significance of the MF features
to model predictions.
On the other hand, the ECFP8-GraphConv-RNN-PSC and ECFP8-GNN-PSC
models demonstrate the effectiveness of the proposed attention-based approach for
integrating multiple unimodal representations of entities for DTI. Similar to the DL
baseline models, more complex JoVA models performed somewhat poorly, albeit less
so in juxtaposition with their baseline analogs. We argue that this is due to the atten-
tion mechanism’s ability to actively encourage learning representations that are highly
related to the learning objective. While the IVPGAN and IntView models attained
the best performance on the Davis dataset, the best performing JoVA models offer the
ability to interpret prediction results via examining the attention weights, aside from
the high prediction performance. Additionally, the reported results of the best JoVA
models seem to imply that the attention-based multi-view representation learning ap-
proach reduces the challenge of the cold splitting schemes. For instance, comparing
the results of the GNN-PSC and ECFP8-GNN-PSC models emphasizes the ability of
JoVA on the cold target scheme. Thus, our proposed method of modeling bioactivity
attains respectable results on the Davis benchmark dataset.
The performance of the baseline and JoVA models on the Metz datasets are shown
in Figure 7. Similar to the general trend of difficulty seen on the Davis dataset, the
cold target regime proved to be the most challenging since the Metz dataset set has
fewer targets (see Table 1). This phenomenon is more evident among the baseline
models than the JoVA models.
Furthermore, the DL-based baselines mostly performed poorly on the Metz dataset.
In particular, the GraphConv-RNN/PCNNA and CPI models attained performances
similar to the KronRLS model. This observation connotes that massive bioactivity
datasets are required in the domain for training unimodal end-to-end DTI models in
order to learn abstract nonlinear patterns from samples properly. It is noteworthy that
while SimBoost edged the multi-view models to become the best performing model,
the nature of SimBoost’s feature engineering phase renders it inapplicable to the cold
splitting schemes. Additionally, while all other baselines and JoVA models maintain
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the hyperparameters identified using the warm splitting scheme of the Davis dataset,
the MF phase of SimBoost uses hyperparameters explicitly identified for the Metz
dataset.
We also observe from Figure 7b that the results of the JoVA models on the Metz
dataset consistently follow their respective results on the Davis dataset. We argue that
this behavior is a direct result of the attention-based multi-view representation learning
approach proposed in this study. Here, the ECFP8-GNN-PSC, ECFP8-GraphConv-
PSC, and ECFP8-GraphConv-RNN-PSC models recorded the best results. An inter-
esting highlight is how the JoVA models’ performances are almost invariable in all
three splitting schemes as compared to the variations seen among the baselines. For
instance, comparing the ECFP8-GNN-PSC JoVA model to the GNN-PSC, ECFP8-
PSC, IVPGAN baselines reify this phenomenon.
Likewise, comparing the CPI (GNN-PCNNA) baseline to the ECFP8-GNN-PCNN2D-
PSC JoVA model gives another perspective into the strengths of our proposed ap-
proach. ECFP8-GNN-PCNN2D-PSC, as could be deduced from our earlier discus-
sions, uses the GNN and PCNN modules of the CPI architecture. However, while CPI
performs poorly on the Metz dataset, the joint view attention mechanism leverages
ECFP8 and PSC to cause better results in the ECFP8-GNN-PCNN2D-PSC model.
On the KIBA dataset, while most of the baselines had varied in their performances
(see Figure 8), the JoVA models performed similarly to the previous experiments. This
demonstrates the consistency of our approach across different datasets. In particular, it
can be seen that the ECFP8-GraphConv-RNN-PSC performed just as well as recorded
on the Metz and Davis datasets. Additionally, in Figures 9-11 also present the plots
of the ECFP8-GraphConv-RNN-PSC model on the three datasets used in this study.
The foregoing performance consistency claim on all three CV splits also agrees with
the scatter and joint plots shown in these figures.
Taken together, we believe that using self-attention to align multiple unimodal
representations of atoms and amino acid residues to each other enables a better rep-
resentational capacity, as is typical of most neural attention-based DL models.
5.1. DrugBank Case Study
In this section, we discuss a case study performed using the Drugbank [82] database.
The ECFP8-GraphConv-RNN-PSC model trained on the KIBA dataset using the
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Figure 6: Davis dataset results. (a) Performance of baseline models. (b) Performance of
JoVA models.
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Figure 7: Metz dataset results. (a) Performance of baseline models. (b) Performance of
JoVA models.
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Figure 8: KIBA dataset results. (a) Performance of baseline models. (b) Performance of
JoVA models.
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Figure 9: ECFP8-GraphConv-RNN-PSC results on the Davis dataset. (From right
to left) Column 1 shows the scatter plots of the ground truth (red line) against predicted
values (blue dots). Column 2 shows the joint distribution plots of the ground truth against
predicted values. The first, second, and third rows correspond to the warm, cold drug, and
cold target splits, respectively.
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Figure 10: ECFP8-GraphConv-RNN-PSC results on the Metz dataset. (From right
to left) Column 1 shows the scatter plots of the ground truth (red line) against predicted
values (blue dots). Column 2 shows the joint distribution plots of the ground truth against
predicted values. The first, second, and third rows correspond to the warm, cold drug, and
cold target splits, respectively.
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Figure 11: ECFP8-GraphConv-RNN-PSC results on the KIBA dataset. (From right
to left) Column 1 shows the scatter plots of the ground truth (red line) against predicted values
(blue dots). Column 2 shows the joint distribution plots of the ground truth against predicted
values. The first, second, and third rows correspond to the warm, cold drug, and cold target
splits, respectively.
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Figure 12: Epidermal Growth Factor Receptor (EGFR-1M17) tyrosine kinase domain in com-
plex with (a) Brigatinib and (b) Zanubrutinib. The amino acid residues in yellow represent
the top-10 subsequences predicted by the JoVA model. For both complexes, the corresponding
interaction analysis of the ligand in the binding pocket of EGFR-1M17 is shown on the right.
The top-10 atoms of ligand predicted by the JoVA model to be influential in the interaction
are depicted in transparent red circles. The amino acids shown in the interaction analysis and
also among the top-10 residues in each complex are highlighted using red circles as borders.
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warm split scheme was selected to evaluate the ability of our approach to predict
novel and existing interactions.
The human Epidermal Growth Factor Receptor (EGFR) was selected to be the
target for the case study. While other targets could equally be chosen, EGFR was
selected since it is implicated in breast cancer and is a popular target for cancer
therapeutics. As regards this Drugbank case study, we refer to both the approved and
investigational drug relations of EGFR as interactions.
We downloaded 13, 339 compounds from the Drugbank database containing 30
interaction records for EGFR. Since the Drugbank database contains small and bio-
logical molecules, we filtered out all biologics. The filtered dataset contained 10, 630
small molecules, of which 21 are reported to target EGFR. Also, we removed all com-
pounds that are present in the KIBA dataset to ensure that all drugs used for the case
study were not part of the training set. As a result, the size of the final Drugbank
dataset used for this case study was 9, 484, with 8 EGFR interactions. Thus, 13 of the
21 small molecules in the Drugbank database are also present in the KIBA dataset.
In table 6 we present the top-50 predictions of the JoVA model. The model was
able to have 6 of the 8 EGFR interactions in its first 50 drugs, ranked according
to the KIBA score. Also, it can be seen that the predicted KIBA scores for all the
reported drugs fall under the KIBA value≤ 3.0 threshold used in [28] to indicate true
interactions. Using the unfiltered 10, 630 small molecules, the predicted KIBA values
of 17 of the 21 EGFR interactions were all below the threshold mentioned above, with
the remaining 4 falling under 4.0.
While these results demonstrate the ability of our proposed approach to improve
the virtual screening stage of drug discovery, the novel predictions reported herein
could become possible cancer therapeutics upon further investigations.
5.2. Interpretability Case Study
As mentioned earlier, the interpretability of DTI predictions could facilitate the
drug discovery process. Also, being able to interpret an interaction in both the com-
pound and target directions of the complex could reveal abstract intermolecular rela-
tionships.
Therefore, we performed an interpretability case study using Brigatinib and Zanubru-
tinib as the ligands and EGFR (Protein Data Bank ID: 1M17) as the macromolecule
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Table 6: The top 50 drugs predicted to interact with the Epidermal Growth Factor Receptor
by the ECFP8-GraphConv-RNN-PSC JoVA model. Entries in bold print are drugs reported
to target EGFR in the Drugbank database. The chemical formula of a drug is used if the
name of the drug is long.
Rank Drugbank ID Drug
KIBA
score
1 DB11963 Dacomitinib 1.314
2 DB06021 AV-412 1.516
3 DB07788 C19H22O7 1.693
4 DB12818 NM-3 1.775
5 DB14944 Tarloxotinib 1.834
6 DB02848 C22H22N4O3S 1.901
7 DB05944 Varlitinib 1.912
8 DB12669 4SC-203 1.915
9 DB12114 Poziotinib 1.993
10 DB14993 Pyrotinib 1.997
11 DB06346 Fiboflapon 2.172
12 DB11652 Tucatinib 2.301
13 DB01933 7-Hydroxystaurosporine 2.414
14 DB12381 Merestinib 2.423
15 DB07270 C20H15Cl2N3O4S 2.467
16 DB06469 Lestaurtinib 2.534
17 DB13517 Angiotensinamide 2.582
18 DB09027 Ledipasvir 2.591
19 DB11747 Barasertib 2.645
20 DB12668 Metenkefalin 2.654
21 DB03482 C28H36N10O15P2 2.692
22 DB11613 Velpatasvir 2.693
23 DB07321 C20H15Cl2N3O5S 2.706
24 DB03005 C42H45N8 2.708
25 DB13088 AZD-0424 2.708
26 DB12673 ATX-914 2.712
27 DB12267 Brigatinib 2.717
28 DB11973 Tesevatinib 2.721
29 DB12706 Seletalisib 2.724
30 DB15343 HM-43239 2.755
31 DB12183 Sapitinib 2.764
32 DB15035 Zanubrutinib 2.764
33 DB15168 Cilofexor 2.772
34 DB06915 C10H8O5 2.777
35 DB11853 Relugolix 2.778
36 DB15407 Acalisib 2.797
37 DB05038 Anatibant 2.821
38 DB14795 AZD-3759 2.837
39 DB06638 Quarfloxin 2.837
40 DB01763 C21H28N7O16P3S 2.857
41 DB15403 Ziritaxestat 2.859
42 DB12557 FK-614 2.859
43 DB07838 C17H12N2O4S2 2.864
44 DB11764 Spebrutinib 2.866
45 DB07698 C18H14ClN5 2.869
46 DB13164 Olmutinib 2.879
47 DB12064 BMS-777607 2.912
48 DB09183 Dasabuvir 2.914
49 DB06666 Lixivaptan 2.934
50 DB06734 Bafilomycin B1 2.937
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in two case studies. The EGFR structure was retrieved from the PDB2 and the ligand
structures from the DrugBank for docking experiments. We used PyRx [83] to perform
in-silico docking and Discovery Studio (v20.1.0) to analyze the docking results. We
then mapped the top-10 atoms and top-10 amino acid residues predicted by the JoVA
model used in the Drugbank case study above unto the docking results. The attention
outputs of the model were used in selecting these top-k segments. In Figure 12, the
yellow sections of the macromolecule indicate the top-10 amino acid residues, whereas
the top-10 atoms of the ligand are shown in red transparent circles in the interaction
analysis results on the right of each complex.
In the case of the EGFR-Brigatinib complex (see Figure 12a), we realized that the
selected amino acid residues were mostly around the binding pocket of the complex.
While we show only the best pose of the ligand in Figure 12, the other selected amino
acid residues were identified by the docking results to be for other poses of the ligand.
Also, selected atoms of the ligand happen to be either involved in an intermolecular
bond or around regions identified by the docking results analysis to be essential for
the interaction. Interestingly, the amino acids of the macromolecule identified to be
intimately involved in the interaction and also among the top-10 residues are predom-
inantly in a Vand der Waals interaction with the ligand. Thus, the model considered
stability of the interaction at the active site to be significant in determining the binding
affinity.
Likewise, the EGFR-Zanubrutinib case study yielded interpretable results upon ex-
amination. It could be seen in Figure 12b that the top-10 amino acid residues selected
in the EGFR-Brigatinib case study were identified again. Thus, the model has learned
to consistently detect the binding site in both case studies. Indeed, this consistency
was also observed in several other experiments using EGFR-1M17 and other ligands3.
This aligns with knowledge in the domain where an active site could be targeted by
multiple ligands. The highlighted top-10 amino acid residues also contain three phos-
phorylation sites (Thr686, Tyr740, Ser744), according to the NetPhos 3.1 [84]4 server
prediction results. Additionally, the interaction analysis of the EGFR-Zanubrutinib
case study reveals that a number of the amino acids selected in the top-10 segments
2https://www.rcsb.org/structure/1M17
3The CSV file containing all the results could be retrieved at https://shorturl.at/guKQZ
4https://services.healthtech.dtu.dk/
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are involved in pi-interactions which are vital to protein-ligand recognition. We also
note that some of the selected atoms of Zanubrutinib are in the aromatic regions where
these pi-interactions take place. In another vein, other selected amino acids are in-
volved in Vand der Waals interactions which reinforce the notion of stability being
significant in determining the binding affinity.
In the nutshell, our approach is also able to offer biologically plausible cues to
experts for understanding DTI interactions. Such an ability could be invaluable in
improving existing virtual screening methods in rational drug discovery.
6. Conclusion
In this study, we have discussed the significance of studying DTI as a regression
problem and also highlighted the advantages that lie within leveraging multiple entity
representations for DTI prediction. Our experimental results indicate the effectiveness
of our proposed self-attention based method in predicting binding affinities and offers
biologically plausible interpretations via the examination of the attention outputs.
The ability to learn rich representations using the self-attention method could have
applications in other cheminformatic and bioinformatic domains such as drug-drug
and protein-protein studies.
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